Генетическая карта здоровья (стр. 6 )

31.        McNamara, D. M., et al., Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol, 2004. 44(10): p. 2019-26.

32.        Wu, C. K., et al., Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J, 2009. 10(1): p. 46-53.

33.        Mollsten, A., B. Stegmayr, and P. G. Wiklund, Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested case-control study. J Hypertens, 2008. 26(7): p. 1367-72.

34.        Poch, E., et al., Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension, 2001. 38(5): p. 1204-9.

35.        Kara, I., et al., Combined effects of ACE and MMP-3 polymorphisms on migraine development. Cephalalgia, 2007. 27(3): p. 235-43.

36.        Thompson, A. R., et al., Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis. Eur J Vasc Endovasc Surg, 2008. 35(1): p. 19-30.

37.        Scharplatz, M., et al., What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review. BMC Med Genet, 2004. 5: p. 23.

38.        Unger, T., The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens, 1999. 17(12 Pt 2): p. 1775-86.

39.        Martin, M. M., et al., The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem, 2007. 282(33): p. 24262-9.

40.        Abdi, R., et al., Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation, 2001. 72(4): p. 726-9.

41.        Diez, J., et al., The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens, 2003. 21(11): p. 2085-92.

42.        Freitas, S. R., et al., Analysis of renin-angiotensin-aldosterone system gene polymorphisms in resistant hypertension. Braz J Med Biol Res, 2007. 40(3): p. 309-16.

43.        Weber, K. T. and C. G. Brilla, Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation, 1991. 83(6): p. 1849-65.

44.        Paillard, F., et al., Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension, 1999. 34(3): p. 423-9.

45.        Casiglia, E., et al., C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J Hypertens, 2005. 23(11): p. 1991-6.

46.        Franco, E., et al., Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age. BMC Med Genet, 2007. 8: p. 27.

47.        Yajnik, C. S., et al., Oral vitamin B12 supplementation reduces plasma total homocysteine concentration in women in India. Asia Pac J Clin Nutr, 2007. 16(1): p. 103-9.

48.        van der Put, N. M., et al., Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet, 1995. 346(8982): p. 1070-1.

49.        James, S. J., et al., Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr, 1999. 70(4): p. 495-501.

50.        Mills, J. L., et al., Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. Am J Med Genet, 1999. 86(1): p. 71-4.

51.        Skibola, C. F., et al., Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A, 1999. 96(22): p. 12810-5.

52.        Lucock, M., Is folic acid the ultimate functional food component for disease prevention? BMJ, 2004. 328(7433): p. 211-4.

53.        Penney, D. S. and K. G. Miller, Nutritional counseling for vegetarians during pregnancy and lactation. J Midwifery Womens Health, 2008. 53(1): p. 37-44.

54.        Catania, J. and D. S. Fairweather, DNA methylation and cellular ageing. Mutat Res, 1991. 256(2-6): p. 283-93.

55.        Vanyushin, B. F., et al., The 5-methylcytosine in DNA of rats. Tissue and age specificity and the changes induced by hydrocortisone and other agents. Gerontologia, 1973. 19(3): p. 138-52.

56.        Costello, J. F. and C. Plass, Methylation matters. J Med Genet, 2001. 38(5): p. 285-303.

57.        Boccia, S., et al., Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett, 2008.

58.        Stidley, C. A., et al., Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res, 2010. 70(2): p. 568-74.

59.        Silaste, M. L., et al., Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr, 2001. 131(10): p. 2643-7.

60.        Laraqui, A., et al., Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. Acta Cardiol, 2006. 61(1): p. 51-61.

61.        Beetstra, S., et al., Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. Cancer Epidemiol Biomarkers Prev, 2008. 17(10): p. 2565-71.

62.        Barbosa, P. R., et al., Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Eur J Clin Nutr, 2008. 62(8): p. 1010-21.

63.        Varga, E. A., B. A. Kerlin, and M. W. Wurster, Social and ethical controversies in thrombophilia testing and update on genetic risk factors for venous thromboembolism. Semin Thromb Hemost, 2008. 34(6): p. 549-61.

64.        Haverkate, F. and M. Samama, Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost, 1995. 73(1): p. 151-61.

65.        van 't Hooft, F. M., et al., Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol, 1999. 19(12): p. 3063-70.

66.        Humphries, S. E., J. A. Henry, and H. E. Montgomery, Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinolysis, 1999. 10 Suppl 1: p. S17-21.

67.        Bots, M. L., et al., Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health, 2002. 56 Suppl 1: p. i14-8.

68.        Sampaio, M. F., et al., AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin Chim Acta, 2007. 377(1-2): p. 154-62.

69.        Scarabin, P. Y., et al., Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb, 1993. 13(6): p. 886-91.

70.        Martiskainen, M., et al., Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke, 2003. 34(4): p. 886-91.

71.        Martinelli, N., et al., Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. PLoS ONE, 2008. 3(2): p. e1523.

72.        Hunt, S. C., et al., Association of the FTO gene with BMI. Obesity (Silver Spring), 2008. 16(4): p. 902-4.

73.        Wardle, J., et al., Obesity Associated Genetic Variation in FTO Is Associated with Diminished Satiety. J Clin Endocrinol Metab, 2008. 93(9): p. 3640-3.

74.        Haupt, A., et al., Variation in the FTO gene influences food intake but not energy expenditure. Exp Clin Endocrinol Diabetes, 2009. 117(4): p. 194-7.

75.        Zabena, C., et al., The FTO Obesity Gene. Genotyping and Gene Expression Analysis in Morbidly Obese Patients. Obes Surg, 2008.

76.        Kring, S. I., et al., FTO gene associated fatness in relation to body fat distribution and metabolic traits throughout a broad range of fatness. PLoS ONE, 2008. 3(8): p. e2958.

77.        Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007. 447(7145): p. 661-78.

78.        Sanghera, D. K., et al., Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med Genet, 2008. 9: p. 59.

79.        Kishimoto, T., The biology of interleukin-6. Blood, 1989. 74(1): p. 1-10.

80.        Kita, M., et al., Induction of cytokines in human peripheral blood mononuclear cells by mycoplasmas. Microbiol Immunol, 1992. 36(5): p. 507-16.

81.        Mysliwska, J., et al., The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res, 2009. 66(3): p. 341-5.

82.        Tischendorf, J. J., et al., The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet, 2007. 34(6): p. 413-8.

83.        Kamarainen, O. P., et al., Common interleukin-6 promoter variants associate with the more severe forms of distal interphalangeal osteoarthritis. Arthritis Res Ther, 2008. 10(1): p. R21.

84.        Naumova, E., et al., Immunological markers contributing to successful aging in Bulgarians. Exp Gerontol, 2004. 39(4): p. 637-44.

85.        Treszl, A., et al., Genetic variants of TNF-[FC12]a, IL-1beta, IL-4 receptor [FC12]a-chain, IL-6 and IL-10 genes are not risk factors for sepsis in low-birth-weight infants. Biol Neonate, 2003. 83(4): p. 241-5.

86.        Schaaf, B. M., et al., Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med, 2003. 168(4): p. 476-80.

87.        Moscovis, S. M., et al., Interleukin-10 and sudden infant death syndrome. FEMS Immunol Med Microbiol, 2004. 42(1): p. 130-8.

88.        Zedan, M., et al., Gene polymorphisms of tumor necrosis factor alpha-308 and interleukin-10-1082 among asthmatic Egyptian children. Allergy Asthma Proc, 2008. 29(3): p. 268-73.

89.        Karjalainen, J., et al., Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clin Exp Allergy, 2003. 33(1): p. 78-83.

90.        Hakansson, A., et al., Investigation of genes coding for inflammatory components in Parkinson's disease. Mov Disord, 2005. 20(5): p. 569-73.

91.        Fernandez, L., et al., Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis, 2005. 11(8): p. 739-43.

92.        Bantis, C., et al., Association of interleukin-10 gene G-1082A polymorphism with the progression of primary glomerulonephritis. Kidney Int, 2004. 66(1): p. 288-94.

93.        Lyssenko, V., et al., Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest, 2007. 117(8): p. 2155-63.

94.        Pilgaard, K., et al., The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia, 2009.

95.        Helgason, A., et al., Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet, 2007. 39(2): p. 218-25.

96.        Tong, Y., et al., Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet, 2009. 10: p. 15.

97.        Florez, J. C., et al., TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med, 2006. 355(3): p. 241-50.

98.        Cui, T., et al., Polymorphisms of IL-4, IL-4R alpha, and AICDA genes in adult allergic asthma. J Huazhong Univ Sci Technolog Med Sci, 2003. 23(2): p. 134-7.

99.        Sandford, A. J., et al., Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol, 2000. 106(1 Pt 1): p. 135-40.

1         Population attributable risk (популяционный добавочный риск) - рассчитывается как произведение добавочного риска на распространенность фактора риска в популяции. Этот показатель отражает дополнительную заболеваемость в популяции, связанную с фактором риска.